Skip to main content
Clinical Trials/NCT01971437
NCT01971437CompletedNot Applicable

A Randomised Study of Cystoscopy and Cystodistension Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome.

Medway NHS Foundation Trust2 sites in 1 country70 target enrollmentStarted: October 1, 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
70
Locations
2
Primary Endpoint
To assess the presence of urgency and urge incontinence initially, 6 weeks and 6 months

Study Overview

Brief Summary

This is an ethically approved randomised controlled study looking at whether Cystodistension(filling the bladder with fluid under pressure) provides any benefit over cystoscopy alone (looking in the bladder) in women with refractory overactive bladder. Urine samples will also be assessed for underlying infected cause of OAB using urinalysis, microscopy and culture and cytokine assays (In collaboration with the University of Kent). We hypothesize that Cystodistension has a therapeutic benefit to women with refractory OAB and the there is an increase prevalence in chronic urinary infections with raised cytokines in women with refractory OAB.

Detailed Description

We aim to measure outcomes initially, 6 weels and 6months follow-up.

  1. Resolution measured by Urgency Perception Scale (UPS). Resolution of urgency will be assessed with the UPS. The numbers of women with a Level 3 UPS score (hold and finish task) will be compared using Chi square test in patients treated with cystodistension vs non cystodistension arms.
  2. Change in quality of life status determined by quality of life questionnaires will ismilarly be comapred between the 2 arms of the study.
  3. Change in urinary symptoms defined by Patient's Perception of Intensity Scale. Change in uregncy scores will be compared between the 2 arms of the study.

Secondary Outcome Measure:1. Prevalence of chronic urinary infection and organisms in patients with refractory OAB 2. To identify whether urinary cytokines are present in a higher proportion of patients with OAB.

Inclusion Criteria

  1. Women with only OAB symptoms
  2. Women who have failed bladder drill and anticholinergic agents
  3. Women who stopped medication due to side-effects or lack of efficacy
  4. Currently receiving no treatment

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women with only OAB symptoms
  • Women who have failed bladder drill and anticholinergic agents
  • Women who stopped medication due to side-effects or lack of efficacy
  • Currently receiving no treatment

Exclusion Criteria

  • Patients with co-existing urodynamic stress incontinence
  • Patients with neurological diseases
  • Patients with pre-existing voiding dysfunction
  • Free flow rate <5th centile or equivalent reduced pressure flow rate OR
  • Post-void residual volume greater than 100ml

Outcomes

Primary Outcomes

To assess the presence of urgency and urge incontinence initially, 6 weeks and 6 months

Time Frame: 12-18months

1. Resolution measured by Urgency Perception Scale. 2. Change in quality of life status. 3. Change in urinary symptoms defined by the Patient's Perception of Intensity Scale

Secondary Outcomes

  • Improved quality of life.(12-18 months)

Investigators

Sponsor
Medway NHS Foundation Trust
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Professor Jonathan Duckett

Consultant Gynaecologist

Medway NHS Foundation Trust

Study Sites (2)

Loading locations...

Similar Trials